Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Vascular Medicine

• Publication date

  2001-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1358836X0100600406PMID 11958389
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar.

  2000cited by this paper
• Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial.

  2000cited by this paper
• Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials.

  2000cited by this paper
• Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar®

  2000cited by this paper
• Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study.

  2000cited by this paper
• Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris.

  2000cited by this paper
• European multicenter study on propionyl-L-carnitine in intermittent claudication.

  1999cited by this paper
• Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.

  1998cited by this paper
• The effect of exercises on walking distance of patients with intermittent claudication: a study of randomized clinical trials.

  1998cited by this paper
• Quality of life in patients with intermittent claudication.

  1996cited by this paper
• Exercise training improves functional status in patients with peripheral arterial disease.

  1996cited by this paper
• Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.

  1996cited by this paper
• Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists.

  1995cited by this paper
• Treatment of intermittent claudication: the impact on quality of life.

  1995cited by this paper
• Impact of intermittent claudication on quality of life. The Scottish Vascular Audit Group.

  1995cited by this paper
• Superiority ofTreadmill Walking Exercise Versus Strength Training forPatients With Peripheral Arterial Disease Implications fortheMechanism oftheTraining Response

  1994cited by this paper
• Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response.

  1994cited by this paper
• Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index.

  1993cited by this paper
• Experience with the preclinical assessment of basic fibroblast growth factor (bFGF).

  1992cited by this paper
• Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor.

  1992cited by this paper
• Pathophysiology and Natural History the Prevalence of Peripheral Arterial Disease in a Defined Population

  year unknowncited by this paper

• Advancements in Gene-Based Therapeutic Angiogenesis for Chronic Limb-Threatening Ischemia

  2025cites this paper
• Optimal injection sites for therapeutic angiogenesis: HGF-mediated regulation of HIF-1α via MAPK/PI3K pathways in hypoxic endothelial cells.

  2025cites this paper
• Micro- and Macrovascular Effects of Inflammation in Peripheral Artery Disease—Pathophysiology and Translational Therapeutic Approaches

  2023cites this paper
• Overcoming ischemia in the diabetic foot: Minimally invasive treatment options

  2021cites this paper
• [Conservative treatment of chronic lower limb ischemia in ambulatory practice (in Russian only)].

  2019cites this paper
• Early pregnancy protein multiplex screening reflects circulating and urinary divergences associated with the development of preeclampsia

  2018cites this paper
• Simvastatin augments revascularization and reperfusion in a murine model of hind limb ischemia - Multimodal imaging assessment.

  2017cites this paper
• Growth factors for angiogenesis in peripheral arterial disease.

  2017cites this paper
• Controlled release of basic fibroblast growth factor for angiogenesis using acoustically-responsive scaffolds.

  2017cites this paper
• Pro-angiogenic effect of RANTES-loaded polysaccharide-based microparticles for a mouse ischemia therapy

  2017cites this paper
• Gene Therapy in Critical Limb Ischemia

  2016cites this paper
• Peripheral Arterial Disease

  2016cites this paper
• Uncoupling angiogenesis and inflammation in peripheral artery disease with therapeutic peptide-loaded microgels.

  2014cites this paper
• Therapeutic angiogenesis for revascularization in peripheral artery disease.

  2013cites this paper
• Development of Poly(Lactide-Co-Glycolide) Microspheres for Controlled Release of Thymosin Beta-4 in the Heart

  2012cites this paper
• Therapeutic Angiogenesis for Critical Limb Ischemia: Complex Mechanisms and Future Challenges

  2012cites this paper
• Thymosin β4 sustained release from poly(lactide‐co‐glycolide) microspheres: synthesis and implications for treatment of myocardial ischemia

  2012cites this paper
• Gene Therapy for Therapeutic Angiogenesis

  2011cites this paper
• Gene Therapy with Non-Viral Vectors For Critical Limb Ischemia: From Bench to Bedside

  2011influential citation
• Controlled-Release Basic Fibroblast Growth Factor for Peripheral Artery Disease: Comparison with Autologous Bone Marrow-Derived Stem Cell Transfer

  2011cites this paper
• Therapeutische Angiogenese bei PAVK - quo vadis?

  2011influential citation
• Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia.

  2010cites this paper
• Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation

  2010cites this paper
• Innocuité et efficacité de l’angiogénèse thérapeutique comme thérapie innovante des patients ayant une ischémie critique des membres inférieurs

  2010cites this paper
• Current Approach to the Diagnosis and Treatment of Femoral-Popliteal Arterial Disease. A Systematic Review

  2009cites this paper
• Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease

  2009cites this paper
• Intradermal delivery of plasmids encoding angiogenic growth factors by electroporation promotes wound healing and neovascularization

  2009cites this paper
• chapter 8 – Natural History and Medical Management of Chronic Lower Extremity Ischemia

  2009cites this paper
• Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptom-directed therapies.

  2009cites this paper
• Mechanical loading impacts intramuscular drug transport : impact on local drug delivery

  2008cites this paper
• Losordo of Age Therapeutic Angiogenesis for Critical Limb Ischemia : Microvascular Therapies Coming

  2008cites this paper
• Continuous local infusion of fibroblast growth factor-2 enhances consolidation of the bone segment lengthened by distraction osteogenesis in rabbit experiment.

  2008cites this paper
• Advances in treating the ischaemic diabetic foot.

  2008cites this paper
• Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age.

  2008cites this paper
• Gene and stem cell therapy in peripheral arterial occlusive disease

  2008cites this paper
• Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction.

  2008cites this paper
• Anti-proteinuric effects of glycosaminoglycan-based drugs.

  2007cites this paper
• Current Management of Peripheral Arterial Occlusive Disease

  2007cites this paper
• Angiogenic growth factors in the treatment of peripheral arterial disease.

  2007cites this paper
• [Therapeutic angiogenesis in the treatment of ischemia of lower extremities].

  2007cites this paper
• Therapeutic Angiogenesis

  2007cites this paper
• Regenerative Medicine of Bone and Teeth : with special references to biological principles, problems and their indicators

  2007cites this paper
• Aberrant heparan sulfate profile in the human diabetic kidney offers new clues for therapeutic glycomimetics.

  2006cites this paper
• ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography

  2006cites this paper
• ORIGINAL RESEARCH—BASIC SCIENCE: Intracavernosal Basic Fibroblast Growth Factor Improves Vasoreactivity in the Hypercholesterolemic Rabbit

  2006cites this paper
• Endovascular treatment of peripheral vascular disease.

  2006cites this paper
• Fibroblast Growth Factor-2

  2006cites this paper
• Beyond angiogenesis: the cardioprotective potential of fibroblast growth factor-2.

  2004cites this paper
• Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation?

  2004cites this paper
• Stimulation of collateral artery growth: a potential treatment for peripheral artery disease

  2004cites this paper
• Angiogenic growth factors and hypertension

  2004cites this paper
• Gene transfer for therapeutic vascular growth in myocardial and peripheral ischemia.

  2004cites this paper
• A novel HIV-1 transgenic rat model of childhood HIV-1-associated nephropathy.

  2003cites this paper
• Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial.

  2003cites this paper
• Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.

  2002cites this paper
• Pharmacologic treatment for intermittent claudication

  2002cites this paper